Brown Advisory Inc. Buys New Shares in Certara, Inc. (NASDAQ:CERT)

Brown Advisory Inc. bought a new position in Certara, Inc. (NASDAQ:CERT - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 24,085 shares of the company's stock, valued at approximately $238,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Envestnet Asset Management Inc. lifted its holdings in Certara by 23.5% during the 1st quarter. Envestnet Asset Management Inc. now owns 511,235 shares of the company's stock worth $5,061,000 after buying an additional 97,179 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in Certara by 2.4% during the 1st quarter. Principal Financial Group Inc. now owns 543,958 shares of the company's stock worth $5,385,000 after buying an additional 12,513 shares in the last quarter. Illinois Municipal Retirement Fund lifted its holdings in Certara by 3.9% during the 1st quarter. Illinois Municipal Retirement Fund now owns 59,721 shares of the company's stock worth $591,000 after buying an additional 2,268 shares in the last quarter. Oppenheimer Asset Management Inc. lifted its holdings in Certara by 25.0% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 221,550 shares of the company's stock worth $2,193,000 after buying an additional 44,270 shares in the last quarter. Finally, Janney Montgomery Scott LLC acquired a new position in Certara during the 1st quarter worth $120,000. 73.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

CERT has been the subject of several recent research reports. KeyCorp dropped their target price on shares of Certara from $18.00 to $15.00 and set an "overweight" rating for the company in a research report on Monday, July 14th. JMP Securities restated a "market perform" rating on shares of Certara in a research report on Tuesday, May 6th. Barclays upgraded shares of Certara from an "equal weight" rating to an "overweight" rating and upped their price objective for the company from $11.00 to $14.00 in a research report on Thursday, May 8th. Morgan Stanley began coverage on shares of Certara in a research report on Thursday, July 3rd. They issued an "equal weight" rating and a $16.00 price objective for the company. Finally, Robert W. Baird upped their price objective on shares of Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a research report on Friday, April 11th. Four analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $15.29.

Certara Stock Performance

Certara stock traded down $0.44 during trading hours on Friday, hitting $10.10. The company had a trading volume of 1,216,002 shares, compared to its average volume of 1,500,700. The firm has a market cap of $1.64 billion, a PE ratio of -505.00 and a beta of 1.43. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.78 and a quick ratio of 2.78. Certara, Inc. has a one year low of $8.64 and a one year high of $16.61. The firm has a 50-day moving average of $11.29 and a 200 day moving average of $11.87.

Certara (NASDAQ:CERT - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.10 by $0.04. Certara had a negative net margin of 0.67% and a positive return on equity of 5.05%. The company had revenue of $106.00 million for the quarter, compared to analysts' expectations of $104.44 million. During the same period last year, the firm earned $0.10 earnings per share. The business's revenue for the quarter was up 9.7% on a year-over-year basis. On average, sell-side analysts expect that Certara, Inc. will post 0.28 earnings per share for the current year.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.